September 2010
PecFent® (Archimedes Pharma Ltd) receives marketing authorization valid throughout Europe
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001164/human_med_001387.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125

December 2009
Effentora® (Cephalon) receives approval for sublingual administration in Europe
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000833/WC500020929.pdf

November 2009
Paper published (online) - Onsolis®
Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Annals of Oncology (published online)
http://www.ncbi.nlm.nih.gov/pubmed/19940014

November 2009
Paper published - Instanyl®:
Mercadante S, Radbruch L, Davies A et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Current Medical Research and Opinion 2009; 25(11); 2805-15
http://informahealthcare.com/doi/pdf/10.1185/03007990903336135

8th October 2009
Paper published (online) - Abstral®
Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Current Medical Research and Opinion (published online)
http://www.ncbi.nlm.nih.gov/pubmed/19814586?dopt=Abstract

20th July 2009
Instanyl® (Nycomed Danmark ApS) receives marketing authorization valid throughout Europe.
http://www.emea.europa.eu/humandocs/Humans/EPAR/instanyl/instanyl.htm

16th July 2009
Onsolis® (Meda Pharmaceuticals Inc) receives FDA approval in United States
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172366.htm